Market revenue in 2023 | USD 82.1 million |
Market revenue in 2030 | USD 235.7 million |
Growth rate | 16.3% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.56% in 2023. Horizon Databook has segmented the UK crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
In February 2016, the UK became the first country to allow genetic modifications in the embryo, along with permitting the legal replacement of embryonic genes with a third person’s genes. The permissions and grants to improve the research in gene editing are expected to propel growth for CRISPR technology in the UK.
However, the safety of gene editing remains a challenge. For instance, some national agencies have stated that genome editing could be used to cause an outbreak of a dangerous disease. Silence Therapeutics, a UK based company, is taking up projects to implement CRISPR to add genes to mice for protein production.
In January 2019, Horizon Discovery, a UK company, received the license to develop a CRISPR-based gene-editing tool from the U.S.-based Rutgers University. In January 2020, the company collaborated with U.S.-based Mammoth Biosciences to access the latter’s CRISPR platform for development of next-generation engineered CHO cell lines.
Horizon Databook provides a detailed overview of country-level data and insights on the UK crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into UK crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account